Cyclerion Therapeutics, Inc.CYCNNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank13
Year-over-Year Change
Year-over-year research & development expense growth
Percentile
P13
Within normal range
vs 5Y Ago
-9.6x
Contraction
Streak
1 yr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| 2024 | -81.12% |
| 2023 | -74.66% |
| 2022 | -84.11% |
| 2021 | -33.29% |
| 2020 | -40.70% |
| 2019 | 8.46% |
| 2018 | 11.31% |
| 2017 | 54.81% |
| 2016 | 0.00% |